BYSI - Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

• BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning in early 2022.
• On Monday morning 9/20/21, BeyondSpring will present at ESMO late breaking Phase 3 trial data on Plinabulin to potentially extend survival for Non-Small Cell Lung Cancer (NSCLC) patients.
• Importantly, FDA approval for CIN by the 11/30/21 PDUFA date will trigger early 2022 commercial launch in the U.S. and give investors greater confidence of FDA approval for NSCLC despite somewhat controversial trial designs.
• Regulatory approvals for Plinabulin for CIN and NSCLC in both the US and China contribute to our estimated revenues of $127, $330 and $638 million in 2022, 2023 and 2024 and EPS of $4/share and a target price of $120/share by 2024.
• Further upside potential from Triple I/O Phase 2 data in Small Cell Lung Cancer (SCLC) in 2022, 7-cancer basket trial Phase 1 data in 2022 and SEED Therapeutics protein degradation.

For further details see: